101 related articles for article (PubMed ID: 30175972)
1. Association between HER2 germline mutation A270S and prognosis in patients with primary breast cancer.
Si P; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Cancer Biomark; 2018; 23(2):165-171. PubMed ID: 30175972
[TBL] [Abstract][Full Text] [Related]
2. HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2-negative patients.
Si P; Chen T; Fang B; Yao J; Liu G; Chen H; Zhai B; Li W
Cancer Med; 2017 Dec; 6(12):2832-2839. PubMed ID: 29072371
[TBL] [Abstract][Full Text] [Related]
3. The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
Toomey S; Madden SF; Furney SJ; Fan Y; McCormack M; Stapleton C; Cremona M; Cavalleri GL; Milewska M; Elster N; Carr A; Fay J; Kay EW; Kennedy S; Crown J; Gallagher WM; Hennessy BT; Eustace AJ
Oncotarget; 2016 Nov; 7(46):75518-75525. PubMed ID: 27776352
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
5. HER2 somatic mutations are associated with poor survival in HER2-negative breast cancers.
Wang T; Xu Y; Sheng S; Yuan H; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Cancer Sci; 2017 Apr; 108(4):671-677. PubMed ID: 28164408
[TBL] [Abstract][Full Text] [Related]
6. Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients.
Xu H; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
BMC Cancer; 2018 Jun; 18(1):662. PubMed ID: 29914420
[TBL] [Abstract][Full Text] [Related]
7. Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.
Chen X; Li Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2018 Oct; 29(10):2046-2051. PubMed ID: 30165555
[TBL] [Abstract][Full Text] [Related]
8. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
Sun J; Meng H; Yao L; Lv M; Bai J; Zhang J; Wang L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Clin Cancer Res; 2017 Oct; 23(20):6113-6119. PubMed ID: 28724667
[No Abstract] [Full Text] [Related]
9. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype.
Theriault RL; Litton JK; Mittendorf EA; Chen H; Meric-Bernstam F; Chavez-Macgregor M; Morrow PK; Woodward WA; Sahin A; Hortobagyi GN; Gonzalez-Angulo AM
Clin Breast Cancer; 2011 Oct; 11(5):325-31. PubMed ID: 21764391
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
11. Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors.
Sinha AK; Patel JR; Shen Y; Ueno NT; Giordano SH; Tripathy D; Lopez DS; Barcenas CH
PLoS One; 2017; 12(1):e0170081. PubMed ID: 28085940
[TBL] [Abstract][Full Text] [Related]
12. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
13. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
15. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
[TBL] [Abstract][Full Text] [Related]
16. Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade.
Ignatov T; Eggemann H; Burger E; Fettke F; Costa SD; Ignatov A
Breast Cancer Res Treat; 2015 Jun; 151(2):357-64. PubMed ID: 25926338
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer.
Sheng S; Xu Y; Guo Y; Yao L; Hu L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jan; 146(2):487-495. PubMed ID: 31119730
[TBL] [Abstract][Full Text] [Related]
18. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
19. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
Reix N; Malina C; Chenard MP; Bellocq JP; Delpous S; Molière S; Sevrin A; Neuberger K; Tomasetto C; Mathelin C
Breast Cancer Res Treat; 2016 Nov; 160(2):249-259. PubMed ID: 27709352
[TBL] [Abstract][Full Text] [Related]
20. HER2 Pro1170Ala polymorphism is associated with decreased survival rate in HER2-negative breast cancer.
Si P; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Oncol Lett; 2017 May; 13(5):3793-3798. PubMed ID: 28529593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]